Case report highlights multidisciplinary approach to recurrent prostate cancer
Case report highlights multidisciplinary approach to recurrent prostate cancer UCLA Health
129 материалов по теме, собраны автоматически из проверенных источников
Case report highlights multidisciplinary approach to recurrent prostate cancer UCLA Health
What Can Help Overcome Treatment Resistance in Advanced Prostate Cancer? - Sylvester Comprehensive Cancer Center Oncodaily
Advanced Radiotherapy as an Alternative to Surgery in Localised Prostate Cancer - The Royal Marsden NHS Foundation Trust oncodaily.com
ASTRO: What New Phase 3 Research Reveals About SBRT for Patients with Localized Prostate Cancer diagnosticimaging.com
Stereotactic body radiation therapy significantly improved quality of life outcomes, including urinary incontinence and sexual function, for men with low- or intermediate-risk prostate cancer compared with prostatectomy. Data from the phase 3 randomized PACE-A trial, presented at the American Society for Radiation…
Five-treatment radiation provides excellent long-term prostate cancer control News-Medical
A rising tide that lifts all boats: PSMA-PET and genomic testing for prostate cancer Urology Times
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer Urology Times
Five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control with fewer urinary and sexual side effects than surgery in the first randomized trial to directly compare the treatments for localized prostate cancer.
Men with high-risk prostate cancer have a higher likelihood of residual disease after prostatectomy and may require radiation therapy after surgery, particularly when PSA levels begin to rise. Conventional postprostatectomy radiotherapy (COPORT) is typically delivered over 37 fractions, while hypofractionated…
A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the PAM50 genomic classifier to determine whether tumor biology could help identify patients most likely to benefit from hormone therapy.
Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes news-medical.net
CIPHER Phase 2 Trial: Carboplatin in HRR-Altered Metastatic Castration-Resistant Prostate Cancer Oncodaily